These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15170741)

  • 21. Engineering mouse T lymphocytes specific to type II collagen by transduction with a chimeric receptor consisting of a single chain Fv and TCR zeta.
    Annenkov A; Chernajovsky Y
    Gene Ther; 2000 Apr; 7(8):714-22. PubMed ID: 10800096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
    Pan JP; Weng YS; Wu QQ
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T-cell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells.
    Heuser C; Hombach A; Lösch C; Manista K; Abken H
    Gene Ther; 2003 Aug; 10(17):1408-19. PubMed ID: 12900755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [In vitro anti-tumor effect of CTL induced by HSP70-Id complex-modified dendritic cells].
    Wang ZH; Ye Q; Hu ZQ; Ye ZQ; Yu X; Shen GX
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):481-5. PubMed ID: 17147108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120.
    Masiero S; Del Vecchio C; Gavioli R; Mattiuzzo G; Cusi MG; Micheli L; Gennari F; Siccardi A; Marasco WA; Palù G; Parolin C
    Gene Ther; 2005 Feb; 12(4):299-310. PubMed ID: 15496956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor.
    Pameijer CR; Navanjo A; Meechoovet B; Wagner JR; Aguilar B; Wright CL; Chang WC; Brown CE; Jensen MC
    Cancer Gene Ther; 2007 Jan; 14(1):91-7. PubMed ID: 17024231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of lymphocytes by anti-CD3 single-chain antibody dimers expressed on the plasma membrane of tumor cells.
    Liao KW; Lo YC; Roffler SR
    Gene Ther; 2000 Feb; 7(4):339-47. PubMed ID: 10694815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generation and characterization of dimeric small immunoproteins specific for neuroblastoma associated antigen GD2.
    Occhino M; Raffaghello L; Burrone O; Gambini C; Pistoia V; Corrias MV; Bestagno M
    Int J Mol Med; 2004 Sep; 14(3):383-8. PubMed ID: 15289889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adoptive T-cell immunotherapy of cancer.
    Li Q; Chang AE
    Cytokines Cell Mol Ther; 1999 Jun; 5(2):105-17. PubMed ID: 10515683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer.
    Scholten KB; Schreurs MW; Ruizendaal JJ; Kueter EW; Kramer D; Veenbergen S; Meijer CJ; Hooijberg E
    Clin Immunol; 2005 Feb; 114(2):119-29. PubMed ID: 15639645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
    Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
    Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
    Biburger M; Weth R; Wels WS
    J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficient lysis of CD44v7/8-presenting target cells by genetically engineered cytotoxic T-lymphocytes--a model for immunogene therapy of cervical cancer.
    Dall P; Hekele A; Beckmann MW; Bender HG; Herrlich P; Ponta H
    Gynecol Oncol; 1997 Aug; 66(2):209-16. PubMed ID: 9264564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunolabeling of CD3-positive lymphocytes with a recombinant single-chain antibody/alkaline phosphatase conjugate.
    Bourin P; Servat A; Lataillade JJ; Goyffon M; Vaux D; Billiald P
    Biol Chem; 2000 Feb; 381(2):173-8. PubMed ID: 10746749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adoptive immunotherapy using autologous lymphocytes sensitized with HLA class I-matched allogeneic tumor cells.
    Yamaguchi Y; Ohshita A; Hironaka K; Okita R; Okawaki M; Matsuura K; Nagamine I; Ikeda T; Ohara M; Hihara J
    Oncol Rep; 2006 Jul; 16(1):165-9. PubMed ID: 16786141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor.
    Prosser ME; Brown CE; Shami AF; Forman SJ; Jensen MC
    Mol Immunol; 2012 Jul; 51(3-4):263-72. PubMed ID: 22503210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene.
    Lamers CH; van Elzakker P; Langeveld SC; Sleijfer S; Gratama JW
    Cytotherapy; 2006; 8(6):542-53. PubMed ID: 17148030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
    Riquelme E; Carreño LJ; González PA; Kalergis AM
    Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.